Life Sciences

MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
7 November 2022

MaaT Pharma Announces Participation in Scientific and Investor Conferences in November

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients...

Read the press release
Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.
17 October 2022

Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.

Clinical Microbiomics, a pioneering microbiome research
company, today announced its acquisition of MS-Omics, a leading metabolomics provider
based in Denmark.

Read the press release
Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners
11 October 2022

Clinical Microbiomics set to accelerate its expansion with EUR 10 million investment from Health for Life Capital™ II” managed by Seventure Partners

Seventure Partners, a worldwide leading microbiome venture capital, and Clinical Microbiomics A/S, a pioneering microbiome research company, today announced the completion of a...

Read the press release
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases
20 July 2022

Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases

Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel targeted live biotherapeutic products (LBPs) to prevent and treat diseases of high unmet...

Read more
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
6 June 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...

Read more
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
6 June 2022

Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022

Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...

Read more
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
2 June 2022

MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...

Read the press release
Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin
24 May 2022

Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin

DERMALA, the only personalized, clinically proven treatment for acne powered by the human microbiome, extends its product range to include a second microbiome-powered line of...

Read more
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
24 May 2022

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced the details...

Read more
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
3 May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Tubulis today announced the successful completion of a €60 million (USD $63 million) Series B financing led by Andera Partners with participation from new investors Evotec...

Read more